Eric Assaraf
PersonRelationship Network
| Connected Entity | Relationship Type |
Strength
(mentions)
|
Documents | Actions |
|---|---|---|---|---|
|
organization
Cowen
|
Employment |
5
|
1 |
HOUSE_OVERSIGHT_024921.jpg
This document is page 105 of a 'Cowen Collaborative Insights' report dated February 25, 2019. It serves as a 'Points of Contact' directory listing the profiles, contact information, and coverage areas for eleven Cowen research analysts. The document bears the Bates stamp 'HOUSE_OVERSIGHT_024921', indicating it was produced during a House Oversight Committee investigation.
HOUSE_OVERSIGHT_024891.jpg
This document is a market research report from Cowen Washington Research Group dated February 25, 2019, authored by Assaraf and watermarked for Michael Cella. It analyzes the regulatory landscape for CBD following the passage of the 2018 Farm Bill, specifically highlighting that while hemp was declassified, the FDA (under Commissioner Scott Gottlieb) retains authority over CBD products making health claims or used in food. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, suggesting it was part of a document production for a Congressional investigation.
HOUSE_OVERSIGHT_024823.jpg
This document is page 7 of a financial research report titled 'Cowen's Collective View of CBD,' dated February 25, 2019. It outlines the anticipated growth of the U.S. CBD market to $16 billion by 2025 and lists various analysts covering specific sectors such as consumer products, pharmacy, and regulation. The document bears a 'HOUSE_OVERSIGHT' stamp, indicating it was likely produced as part of a congressional investigation, possibly related to banking records, though the text itself contains no direct references to Jeffrey Epstein.
HOUSE_OVERSIGHT_024822.jpg
This document is the Table of Contents for a 'Cowen Collaborative Insights' research report dated February 25, 2019, focusing on the CBD and Cannabis market. The report covers various sectors including consumer products, healthcare, and global landscapes, with sections attributed to specific analysts (e.g., Azer, Nadeau, Schenkel). The document bears a 'HOUSE_OVERSIGHT_024822' Bates stamp, indicating it is part of a document production to the House Oversight Committee, likely related to investigations into financial records.
HOUSE_OVERSIGHT_024821.jpg
This Cowen report page discusses the global regulatory landscape for CBD, highlighting developments in Europe and Latin America, and analyzes the U.S. regulatory outlook following the 2018 Farm Bill. It details the shifting oversight from the DEA to the Department of Agriculture while noting continued FDA authority and regulatory uncertainty regarding CBD products.
HOUSE_OVERSIGHT_024819.jpg
A Cowen equity research report titled 'Cowen's Collective View of CBD - Ahead of the Curve Series,' dated February 25, 2019. The document analyzes the U.S. CBD market, projecting a $16 billion opportunity by 2025, and discusses consumer trends, scientific understanding, and hemp cultivation. The document bears a House Oversight Committee Bates stamp (HOUSE_OVERSIGHT_024819) and a watermark indicating it was intended for Michael Cella at Cowen.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity